Larvol Veri

CANCER:

Ocular Melanoma

Related cancers:

‹

Melanoma (790)

Uveal Melanoma (74)

Cutaneous Melanoma (70)

Mucosal Melanoma (16)

Melanoma (790)

Uveal Melanoma (74)

Cutaneous Melanoma (70)

Mucosal Melanoma (16)

›

No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	TC Sensitive: A2 - Guideline TC Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline ipilimumab Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline dacarbazine Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	temozolomide Sensitive: A2 - Guideline temozolomide Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: A2 - Guideline trametinib Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline albumin-bound paclitaxel Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline nivolumab + ipilimumab Sensitive : A2
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	CaT Sensitive: A2 - Guideline CaT Sensitive : A2
HLA-A positive HLA-A positive	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: B - Late Trials IMCgp100 Sensitive : B
BRAF V600 BRAF V600	Ocular Melanoma Ocular Melanoma	vemurafenib Sensitive: C1 - Off-label vemurafenib Sensitive : C1
BRAF V600 BRAF V600	Ocular Melanoma Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
BRAF V600E BRAF V600E	Ocular Melanoma Ocular Melanoma	trametinib + dabrafenib Sensitive: C1 - Off-label trametinib + dabrafenib Sensitive : C1
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria selumetinib Sensitive : C2
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria trametinib Sensitive : C2
MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
CXCL10 elevation CXCL10 elevation	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: C3 – Early Trials IMCgp100 Sensitive : C3
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials IDE196 Sensitive : C3
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES

VERI is free for non-commercial use, no login needed.

Content on this site is for research purposes only and is not intended to be a substitute for medical advice.

For commercial access, including additional premium features, please contact us.

By using VERI, you are agreeing to our

and

ACCEPT COOKIES